CAJ | 학술논문

目的研究细胞色素P450酶1A2(CYP1A2)基因C734A及G-2964A位点多态性与度洛西汀临床疗效的关系.方法用度洛西汀对223例抑郁症患者进行为期6周的治疗,用汉密尔顿抑郁量表(HAMD)评定疗效,聚合酶链反应扩增及限制性片段长度多态性(PCR-RFLP)检测CYP1 A2基因C734A及G-2964A位点单核苷酸多态性,用单因素方差分析分析两者的关系.结果 (1)223例患者中,C734A突变率为63.64％,G-2964A突变率为26.82％.(2)共计220例患者完成全程治疗.两突变位点联合分析结果表明,高活性组、中间活性组及低活性组在治疗后的HAMD减分率分别为(56.05± 10.13)％、(66.36±8.66)％和(73.82±7.10)％,3组之间两两比较均差异具有统计学意义(均P＜0.01).结论 CYP1A2基因C734A及G-2964A位点多态性与度洛西汀治疗抑郁症的临床疗效密切相关.
목적 연구세포색소P450매1A2(CYP1A2)기인C734A급G-2964A위점다태성여도락서정림상료효적관계.방법 용도락서정대223례억욱증환자진행위기6주적치료,용한밀이돈억욱량표(HAMD)평정료효,취합매련반응확증급한제성편단장도다태성(PCR-RFLP)검측CYP1 A2기인C734A급G-2964A위점단핵감산다태성,용단인소방차분석분석량자적관계.결과 (1)223례환자중,C734A돌변솔위63.64％,G-2964A돌변솔위26.82％.(2)공계220례환자완성전정치료.량돌변위점연합분석결과표명,고활성조、중간활성조급저활성조재치료후적HAMD감분솔분별위(56.05± 10.13)％、(66.36±8.66)％화(73.82±7.10)％,3조지간량량비교균차이구유통계학의의(균P＜0.01).결론 CYP1A2기인C734A급G-2964A위점다태성여도락서정치료억욱증적림상료효밀절상관.
Objective To investigate the relationship between C734A and G-2964A polymorphism of cytochrome P450 1A2 gene and clinical efficacy of duloxetine.Methods 223 patients with depression were treated with duloxetine for six weeks.The clinical efficacy was evaluated with the Hamilton rating scale for depression (HAMD) ;single nucleotide polymorphism (SNP) at position C734A and G-2964A of CYP1A2 gene were identified with restriction fragment length polymorphism(RFLPs) ;then one-way ANOVA was adopted to analyze the relationship between SNP and clinical efficacy.Results (1) In 223 patients,the frequency of allele A at locus 734 was 63.64％,while that of allele A at locus-2964 was 26.82％.(2) 220 patient underwent the whole treating course.The conjoint analysis of two locuses indicated that the decreasing ratio of HAMD score of high-activity group,middle-activity group and low-activity after treatment was (56.05± 10.13) ％,(66.36± 8.66) ％ and (73.82± 7.10) ％ respectively,the differences obtained by pairwise comparison of the three groups were of statistical significance(P＜0.01).Conclusion There is close relationship between C734A and G-2964A polymorphism of CYP1A2 gene and clinical efficacy of duloxetine in the treatment for depression.